In an infant with ambiguous genitalia, how can I differentiate classic 21‑hydroxylase‑deficient congenital adrenal hyperplasia (CAH) from complete androgen‑insensitivity syndrome (CAIS), and what are the initial diagnostic tests and management steps for each condition?

Differentiating CAH from CAIS in Ambiguous Genitalia

In an infant with ambiguous genitalia, measure 17-hydroxyprogesterone (17-OHP) and obtain a karyotype immediately—elevated 17-OHP (>300 nmol/L or >10,000 ng/dL) with 46,XX karyotype confirms classic CAH, while 46,XY karyotype with normal/low 17-OHP and high testosterone suggests CAIS.

Key Clinical Distinctions

Classic CAH (21-hydroxylase deficiency)

• Karyotype: 46,XX (genetic female)
• Genital appearance: Virilized external genitalia with clitoromegaly and labial fusion
• Internal structures: Normal uterus and ovaries present
• Life-threatening risk: 75% develop salt-wasting crisis with hypovolemia, hyponatremia, and hyperkalemia within first 2-4 weeks of life 1

Complete AIS

• Karyotype: 46,XY (genetic male)
• Genital appearance: Typically female or mildly ambiguous external genitalia
• Internal structures: Absent uterus, testes present (may be intra-abdominal or inguinal)
• No adrenal crisis risk: Normal cortisol and aldosterone production

Initial Diagnostic Algorithm

Step 1: Immediate Laboratory Tests (within 24-48 hours)

1. Serum 17-OHP (preferably by LC-MS/MS after initial immunoassay) 1
2. Karyotype (standard or rapid FISH)
3. Serum electrolytes (sodium, potassium)
4. Plasma renin activity
5. Testosterone and androstenedione

Step 2: Interpretation of 17-OHP Levels 1

Baseline 17-OHP interpretation:

• >300 nmol/L (>10,000 ng/dL): Likely classic CAH
• 6-300 nmol/L (200-10,000 ng/dL): Likely nonclassic CAH or equivocal
• <6 nmol/L (<200 ng/dL): CAH unlikely

If equivocal, perform ACTH stimulation test:

• Post-stimulation 17-OHP >300 nmol/L (>10,000 ng/dL): Confirms classic CAH 1
• Post-stimulation 17-OHP 31-300 nmol/L: Suggests nonclassic CAH
• Post-stimulation 17-OHP <50 nmol/L (<1,666 ng/dL): Excludes CAH

Step 3: Imaging

• Pelvic ultrasound: Identify uterus (present in CAH, absent in CAIS) and gonads
• Genitography (if needed): Assess urogenital sinus anatomy in CAH

Critical Management Steps

For Confirmed Classic CAH (Life-Saving Priority)

Immediate treatment to prevent adrenal crisis and death 1:

1. Glucocorticoid replacement (start immediately, do not wait for confirmatory tests if clinical suspicion high):

   • Hydrocortisone 10-15 mg/m²/day divided TID 1
   • Initial doses may be higher to rapidly suppress androgens, then taper quickly

2. Mineralocorticoid replacement (all classic CAH patients) 1:

   • Fludrocortisone 0.05-0.2 mg/day (1-2 times daily)
   • Sodium chloride supplements 1-2 g/day (17-34 mEq/day) in infancy, divided in feedings

3. Monitor electrolytes closely: Daily initially, then every 2-3 days until stable

4. Stress dosing education: Triple hydrocortisone dose for fever >38.5°C, gastroenteritis with dehydration, surgery, or major trauma 1

Common pitfall: Males with salt-wasting CAH have normal-appearing genitalia and are frequently missed without newborn screening, leading to preventable deaths from adrenal crisis 1, 2. The death rate without screening is 4-10% 1.

For Suspected CAIS

1. Confirm diagnosis: Elevated testosterone with normal/high LH, normal 17-OHP
2. Locate gonads: Ultrasound or MRI to identify testicular tissue
3. Gonadectomy timing: Controversial—can defer until after puberty (tumor risk <1%) or perform early depending on family preference 3
4. No immediate medical emergency: Unlike CAH, CAIS does not cause adrenal insufficiency

Genotyping Considerations

Reserve genetic testing for 1:

• Equivocal hormonal results
• Genetic counseling for future pregnancies
• Prenatal diagnosis planning

CAH genotype-phenotype correlation: CYP21A2 mutations determine severity, but compound heterozygotes may have variable phenotypes 1. Genotyping cannot predict salt-wasting vs. simple virilizing forms reliably.

Newborn Screening Context

All states in the US screen for CAH using two-tier protocol 1:

• Initial immunoassay followed by LC-MS/MS confirmation
• 14% of classic CAH cases detected only on second routine screen 4
• Screening reduces time to diagnosis and prevents mortality, especially in males 1, 2

However: Newborn screening can be falsely negative in some cases 5, so clinical suspicion with ambiguous genitalia mandates immediate diagnostic workup regardless of screening results.

Long-term Surgical Considerations

CAH

• Timing controversial: Early single-stage feminizing genitoplasty (clitoroplasty + vaginoplasty) in infancy vs. delayed until patient can consent 1, 3
• Endocrine Society recommendation: Early surgery by experienced surgeons for severely virilized girls, emphasizing function over cosmesis 1
• Risk: High vaginal stenosis rate with prepubertal vaginoplasty; newer techniques using urogenital sinus mucosa may reduce scarring 3

CAIS

• Gonadectomy timing individualized based on family preference and psychological considerations 3